ALOX5 and hyperinsulinemic hypoglycemia, familial, 4: Considering that Alox5−/− animals lack all 5-LO-derived metabolites and LTB4 is the major product of this pathway (Samuelsson, 2000), we performed a pharmacological treatment with this lipid mediator to evaluate its specific involvement on the altered biological and behavioral responses due to 5-LO deficiency (Supplementary Figure S2).